HK1198255A1 - 與磷脂酰絲氨酸結合的 融合構建體及其治療用途 - Google Patents
與磷脂酰絲氨酸結合的 融合構建體及其治療用途Info
- Publication number
- HK1198255A1 HK1198255A1 HK14111797.6A HK14111797A HK1198255A1 HK 1198255 A1 HK1198255 A1 HK 1198255A1 HK 14111797 A HK14111797 A HK 14111797A HK 1198255 A1 HK1198255 A1 HK 1198255A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- phosphatidylserine
- disease treatment
- constructs binding
- constructs
- binding
- Prior art date
Links
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 title 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64633305P | 2005-01-24 | 2005-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1198255A1 true HK1198255A1 (zh) | 2015-03-20 |
Family
ID=36693034
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14111797.6A HK1198255A1 (zh) | 2005-01-24 | 2014-11-21 | 與磷脂酰絲氨酸結合的 融合構建體及其治療用途 |
HK15105389.1A HK1205133A1 (zh) | 2005-01-24 | 2015-06-05 | 與磷脂酰絲氨酸結合的 融合構建體及其治療用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105389.1A HK1205133A1 (zh) | 2005-01-24 | 2015-06-05 | 與磷脂酰絲氨酸結合的 融合構建體及其治療用途 |
Country Status (14)
Country | Link |
---|---|
US (3) | US8956616B2 (zh) |
EP (1) | EP1853631B1 (zh) |
JP (2) | JP5127043B2 (zh) |
CN (3) | CN101146826A (zh) |
AU (1) | AU2006206187B2 (zh) |
CA (1) | CA2591914C (zh) |
DK (1) | DK1853631T3 (zh) |
ES (1) | ES2565543T3 (zh) |
HK (2) | HK1198255A1 (zh) |
IL (1) | IL184406A (zh) |
NZ (1) | NZ556065A (zh) |
SG (1) | SG158919A1 (zh) |
SI (1) | SI1853631T1 (zh) |
WO (1) | WO2006079120A2 (zh) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050222030A1 (en) * | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
US20090291086A1 (en) * | 2001-02-21 | 2009-11-26 | Alavita Pharmaceuticals, Inc. | Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia |
GB0707034D0 (en) * | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
DK2164992T3 (en) * | 2007-05-30 | 2016-08-15 | Lpath Inc | COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
EP2209420A4 (en) | 2007-10-09 | 2014-01-22 | Univ St Louis | IMAGING PARTICLES |
US9468607B2 (en) | 2007-10-09 | 2016-10-18 | Washington University | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
EP2222277A4 (en) * | 2007-11-15 | 2014-10-15 | Biolitec Pharma Ip & Invest Ltd | PGEYLATED LIPOSOMAL FORMULATIONS FOR THE PHOTODYNAMIC TREATMENT OF INFLAMMATORY DISEASES |
GB0723797D0 (en) * | 2007-12-05 | 2008-01-16 | Immunosolv Ltd | Method |
US8551489B2 (en) | 2008-01-03 | 2013-10-08 | Musc Foundation For Research Development | Methods for the treatment of cancers |
JP2011518124A (ja) * | 2008-03-26 | 2011-06-23 | ユニバーシティ・オブ・オックスフォード | 小胞体ターゲッティングリポソーム |
GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
NZ602824A (en) | 2008-12-05 | 2014-05-30 | Abraxis Bioscience Llc | Sparc binding peptides and uses thereof |
WO2011036467A1 (en) * | 2009-09-24 | 2011-03-31 | Russell David Keenan | Products useful in the treatment of haemophilia |
WO2011069090A1 (en) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
US9764043B2 (en) | 2009-12-17 | 2017-09-19 | Washington University | Antithrombotic nanoparticle |
US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
EP2369551B1 (en) * | 2010-03-25 | 2019-10-30 | Emory University | Imaging system and method |
AU2011239414A1 (en) | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
CN105524176B (zh) * | 2010-05-21 | 2021-03-19 | 银溪制药股份有限公司 | 双特异性融合蛋白 |
WO2012030949A2 (en) * | 2010-09-01 | 2012-03-08 | Kansas State University Research Foundation | B2-glycoprotein i peptide inhibitors |
JP6170047B2 (ja) | 2011-08-31 | 2017-07-26 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポトーシス−ターゲティングナノ粒子 |
US9463217B1 (en) * | 2012-02-10 | 2016-10-11 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and pharmaceutical compositions for treatment of retinal occlusion |
ES2669561T3 (es) | 2012-02-17 | 2018-05-28 | University Of Georgia Research Foundation, Inc. | Nanopartículas para el transporte mitocondrial de agentes |
CA2879542A1 (en) * | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
US20140287024A1 (en) * | 2013-03-08 | 2014-09-25 | Shu Wang | Nanoparticle-based delivery system with oxidized phospholipids as targeting ligands for the prevention, diagnosis and treatment of atherosclerosis |
HUE062021T2 (hu) * | 2013-03-15 | 2023-09-28 | Gladiator Biosciences Inc | GLA domének mint targetáló szerek |
GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
JP6685225B2 (ja) | 2013-12-16 | 2020-04-22 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 形質細胞様樹状細胞の枯渇 |
WO2015138992A1 (en) | 2014-03-14 | 2015-09-17 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
US11491480B2 (en) | 2014-06-13 | 2022-11-08 | Children's Medical Center Corporation | Products and methods to isolate mitochondria |
WO2017185662A1 (zh) * | 2016-04-29 | 2017-11-02 | 深圳市中联生物科技开发有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
EP3292140B1 (en) * | 2015-05-05 | 2022-04-20 | Rubicon Biotechnology LLC | Cancer immunotherapeutic |
EP3307243A4 (en) * | 2015-06-09 | 2019-01-02 | The Board of Regents of The University of Texas System | Diagnostic test for early stage cancer |
ES2863278T3 (es) | 2015-10-02 | 2021-10-11 | Silver Creek Pharmaceuticals Inc | Proteínas terapéuticas biespecíficas para la reparación de tejidos |
CN108430499B (zh) * | 2015-12-15 | 2022-07-19 | 肿瘤免疫股份有限公司 | 嵌合和人源化抗人类ctla4单克隆抗体和其用途 |
WO2017124037A1 (en) * | 2016-01-15 | 2017-07-20 | The Children's Medical Center Corporation | Therapeutic use of mitochondria and combined mitochondrial agents |
WO2017133018A1 (zh) * | 2016-02-06 | 2017-08-10 | 法玛科技顾问股份有限公司 | 重组β2-糖蛋白胜肽及其于抗肿瘤的应用 |
CN109689692B (zh) | 2016-06-22 | 2021-11-12 | 本康生物制药(深圳)有限公司 | 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用 |
EA038617B1 (ru) * | 2016-07-06 | 2021-09-23 | Онкоиммьюн, Инк. | Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование |
RU2019112860A (ru) | 2016-09-27 | 2020-10-30 | Серо Терапьютикс, Инк. | Молекулы химерных интернализационных рецепторов |
CA3037008A1 (en) | 2016-09-27 | 2018-04-05 | Oncologie, Inc. | Methods for treating cancer with bavituximab based on levels of .beta.2-glycoprotein 1, and assays therefor |
EP3606960A1 (en) * | 2017-04-03 | 2020-02-12 | Oncologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
CN108727489B (zh) * | 2017-04-19 | 2021-02-09 | 广州市第八人民医院 | 一种单克隆抗体zk2c2及应用 |
US11352404B2 (en) * | 2017-07-24 | 2022-06-07 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
US11661447B2 (en) | 2017-08-03 | 2023-05-30 | The Cleveland Clinic Foundation | Human β2-glycoprotein I expression |
CA3074678A1 (en) * | 2017-09-05 | 2019-03-14 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
RU2020114641A (ru) | 2017-09-26 | 2021-10-27 | Серо Терапьютикс, Инк. | Молекулы химерных интернализационных рецепторов и способы применения |
CN108021784B (zh) * | 2017-12-01 | 2021-05-11 | 大连理工大学 | 纳米金属氧化物光致产生活性氧物种的预测方法 |
ES2727261B2 (es) * | 2018-04-12 | 2020-05-06 | Fundacion Para La Investig Biomedica Del Hospital 12 De Octubre | INMUNOCOMPLEJOS ARTIFICIALES Y SU USO COMO CALIBRES EN SISTEMAS DE DETECCION DE INMUNOCOMPLEJOS CIRCULANTES B2GP1-aB2GP1 |
US20220000780A1 (en) * | 2018-11-08 | 2022-01-06 | Mahmoud Nasr | Nanodiscs for preventing and treating pathogen infections and methods of use thereof |
WO2020114614A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
TW202039583A (zh) | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | 結合因子IXa及因子X的蛋白分子 |
EP3711772A1 (en) * | 2019-03-20 | 2020-09-23 | Oslo Universitetssykehus HF | Recombinant proteins and fusion proteins |
WO2020264181A1 (en) * | 2019-06-28 | 2020-12-30 | The Board Of Regents Of The University Of Oklahoma | Therapeutic annexin-drug conjugates and methods of use |
US20220033426A1 (en) * | 2020-07-28 | 2022-02-03 | Yale University | Transition Metal Macrocyclics as MRI Contrast Agents for Molecular Imaging |
WO2022040635A1 (en) * | 2020-08-21 | 2022-02-24 | The University Of Chicago | Nanoparticles containing multiple cleavable produgs for cancer therapy |
US20220261990A1 (en) * | 2021-02-05 | 2022-08-18 | Viqi, Inc. | Machine learning for early detection of cellular morphological changes |
CN114002133B (zh) * | 2021-10-25 | 2023-01-24 | 南京大学 | 血清中ps阳性外泌体作为乳腺癌化疗敏感性标志物的应用 |
WO2023141524A2 (en) * | 2022-01-19 | 2023-07-27 | Lyndra Therapeutics, Inc. | Dosage forms for gastric retention |
CN114288399B (zh) * | 2022-01-20 | 2023-10-27 | 武汉科技大学 | 一种嵌合抗原受体联合抗肿瘤药物组合物及其应用 |
US20230324382A1 (en) * | 2022-02-01 | 2023-10-12 | Trustees Of Tufts College | Antiphospholipid antibodies for the diagnosis of lyme disease |
WO2023150672A1 (en) * | 2022-02-04 | 2023-08-10 | Duke University | Compositions for and methods of treating hematological cancers |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
CA2058769C (en) * | 1990-04-06 | 1999-03-02 | Steven Anthony Krilis | Methods for determining phospholipids and antibodies thereof |
CA2107557C (en) * | 1992-02-05 | 1999-07-20 | Eiji Matsuura | Solid phase reagent and assay method for antibody using the same |
WO1994013323A1 (en) | 1992-12-04 | 1994-06-23 | The Liposome Company, Inc. | Method of inhibiting the clearance of liposomes from the circulation |
FR2701319B1 (fr) * | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé de détection et/ou de dosage de composés viraux et support portant une glycoprotéine. |
FR2701263B1 (fr) * | 1993-02-09 | 1995-04-21 | Elie Stefas | Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps. |
JP3370334B2 (ja) * | 1993-09-29 | 2003-01-27 | 栄次 松浦 | 酸化リポタンパク質の測定法およびその用途 |
AU696638B2 (en) * | 1993-11-16 | 1998-09-17 | Yamasa Corporation | Method of assaying antiphospholipid antibody and kit therefor |
JP3524929B2 (ja) * | 1994-08-01 | 2004-05-10 | インスティテュート デ ルシェルシュ ポル レ ドゥベロップマン | 感染性化合物の分離および/または検出および/または定量を行うための方法およびこの方法を実施するための支持体 |
FR2722991B1 (fr) | 1994-08-01 | 1996-10-11 | Orstom | Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante |
US5817789A (en) * | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
US6203980B1 (en) * | 1998-02-02 | 2001-03-20 | University Of Pittsburgh | Identification of apolipoprotein H mutations and their diagnostic uses |
US6858210B1 (en) * | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
IL125262A0 (en) * | 1998-07-07 | 1999-03-12 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
JP2000028607A (ja) | 1998-07-10 | 2000-01-28 | Iatron Lab Inc | 新規なモノクローナル抗体及びニックβ2グリコプロテインIの免疫学的分析方法 |
CA2333147C (en) * | 1998-07-13 | 2012-02-07 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
BR9912053A (pt) * | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US20050197283A1 (en) * | 1998-10-04 | 2005-09-08 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease |
US20050148499A1 (en) | 1998-10-04 | 2005-07-07 | Dror Harats | Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of atherosclerosis |
IL126447A (en) * | 1998-10-04 | 2004-09-27 | Vascular Biogenics Ltd | An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis |
AUPQ272699A0 (en) | 1999-09-09 | 1999-09-30 | Unisearch Limited | Use of beta2GPI in diagnostic tests for autoimmune diseases |
US7600039B2 (en) * | 2000-02-16 | 2009-10-06 | Motorola, Inc. | Label-based multiplexing |
EP1263982A4 (en) | 2000-03-08 | 2005-03-09 | Nat Jewish Med & Res Center | PHOSPHATIDYL SERIN RECEPTORS AND ITS APPLICATIONS |
CN1434726A (zh) * | 2000-06-08 | 2003-08-06 | 拉卓拉药物公司 | 包含高分子量聚环氧乙烷的多价平台分子 |
ES2649037T3 (es) * | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
ES2296914T3 (es) | 2001-01-26 | 2008-05-01 | The General Hospital Corporation | Farmacos de serpina para el tratamiento de la infeccion por vih y metodo de uso de los mismos. |
WO2002100445A1 (en) | 2001-06-13 | 2002-12-19 | The University Of Sydney | Treatment and composition for wound healing |
FR2827047B1 (fr) * | 2001-07-03 | 2003-09-26 | Apoh Technollgies Sa | Procede de separation et/ou detection et/ou identification et/ou quantification de proteines prions |
JP4681175B2 (ja) | 2001-09-28 | 2011-05-11 | 三菱化学メディエンス株式会社 | 播種性血管内凝固症候群及びその発症前段階を検出する方法 |
JP4070443B2 (ja) * | 2001-10-11 | 2008-04-02 | 株式会社三菱化学ヤトロン | 脳梗塞を検出する方法 |
US20030100036A1 (en) * | 2001-11-08 | 2003-05-29 | Aristo Vojdani | Saliva immunoassay for detection of antibodies for cardiovascular disease |
WO2003044482A2 (en) * | 2001-11-16 | 2003-05-30 | The University Of Tennessee Research Corporation | Recombinant antibody fusion proteins and methods for detection of apoptotic cells |
WO2003099833A2 (en) | 2002-05-17 | 2003-12-04 | Board Of Regents, The University Of Texas System | Beta-2-glycoprotein 1 is an inhibitor of angiogenesis |
ES2358730T3 (es) | 2002-07-15 | 2011-05-13 | Board Of Regents, The University Of Texas System | Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer. |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7611704B2 (en) * | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7247303B2 (en) * | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
US7790159B2 (en) * | 2002-07-15 | 2010-09-07 | Board Of Regents, The University Of Texas System | Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids |
US7455833B2 (en) * | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7906115B2 (en) * | 2002-07-15 | 2011-03-15 | Thorpe Philip E | Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
AU2003251238A1 (en) * | 2002-08-07 | 2004-02-25 | Umc Utrecht Holding B.V. | Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha |
DK2298347T3 (en) | 2003-05-06 | 2016-01-11 | Biogen Hemophilia Inc | COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER |
WO2005019429A2 (en) * | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
WO2006109312A2 (en) | 2005-04-15 | 2006-10-19 | Vascular Biogenics Ltd. | Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
AU2006236403B2 (en) * | 2005-04-18 | 2011-11-10 | Bio-Rad Laboratories, Inc. | Solid phase immobilization of phospholipids and cofactor proteins via covalent attachment |
-
2006
- 2006-01-24 AU AU2006206187A patent/AU2006206187B2/en not_active Ceased
- 2006-01-24 EP EP06719706.1A patent/EP1853631B1/en not_active Not-in-force
- 2006-01-24 ES ES06719706.1T patent/ES2565543T3/es active Active
- 2006-01-24 SI SI200632035T patent/SI1853631T1/sl unknown
- 2006-01-24 CA CA2591914A patent/CA2591914C/en not_active Expired - Fee Related
- 2006-01-24 NZ NZ556065A patent/NZ556065A/en unknown
- 2006-01-24 JP JP2007552418A patent/JP5127043B2/ja not_active Expired - Fee Related
- 2006-01-24 CN CNA2006800070648A patent/CN101146826A/zh active Pending
- 2006-01-24 CN CN201410301233.5A patent/CN104109209B/zh not_active Expired - Fee Related
- 2006-01-24 WO PCT/US2006/002964 patent/WO2006079120A2/en active Application Filing
- 2006-01-24 DK DK06719706.1T patent/DK1853631T3/en active
- 2006-01-24 US US11/339,392 patent/US8956616B2/en active Active
- 2006-01-24 SG SG201000541-1A patent/SG158919A1/en unknown
- 2006-01-24 CN CN201410333397.6A patent/CN104277117A/zh not_active Withdrawn
-
2007
- 2007-07-04 IL IL184406A patent/IL184406A/en not_active IP Right Cessation
-
2012
- 2012-03-14 JP JP2012057880A patent/JP2012111783A/ja not_active Withdrawn
-
2014
- 2014-11-21 HK HK14111797.6A patent/HK1198255A1/zh not_active IP Right Cessation
-
2015
- 2015-02-02 US US14/611,634 patent/US20160015826A1/en not_active Abandoned
- 2015-06-05 HK HK15105389.1A patent/HK1205133A1/zh unknown
-
2016
- 2016-07-12 US US15/207,955 patent/US20160311886A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006206187A1 (en) | 2006-07-27 |
WO2006079120A2 (en) | 2006-07-27 |
CN104109209B (zh) | 2016-06-08 |
DK1853631T3 (en) | 2016-03-29 |
US20060228299A1 (en) | 2006-10-12 |
IL184406A (en) | 2014-11-30 |
ES2565543T3 (es) | 2016-04-05 |
JP5127043B2 (ja) | 2013-01-23 |
NZ556065A (en) | 2009-04-30 |
CN101146826A (zh) | 2008-03-19 |
SI1853631T1 (sl) | 2016-04-29 |
HK1205133A1 (zh) | 2015-12-11 |
EP1853631A2 (en) | 2007-11-14 |
US8956616B2 (en) | 2015-02-17 |
CA2591914C (en) | 2017-04-25 |
EP1853631B1 (en) | 2016-03-09 |
AU2006206187B2 (en) | 2011-03-10 |
SG158919A1 (en) | 2010-02-26 |
JP2008528521A (ja) | 2008-07-31 |
WO2006079120A3 (en) | 2007-07-19 |
CA2591914A1 (en) | 2006-07-27 |
CN104109209A (zh) | 2014-10-22 |
JP2012111783A (ja) | 2012-06-14 |
CN104277117A (zh) | 2015-01-14 |
US20160015826A1 (en) | 2016-01-21 |
IL184406A0 (en) | 2008-12-29 |
US20160311886A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1205133A1 (zh) | 與磷脂酰絲氨酸結合的 融合構建體及其治療用途 | |
IL195675A0 (en) | Human binding molecules having killing activity against staphylococci and uses thereof | |
IL190332A0 (en) | Human antibodies against il13 and therapeutic uses | |
IL177847A0 (en) | Use of lipid conjugates in the treatment of disease | |
EP1895946A4 (en) | IMPROVEMENTS FROM AND RELATED TO SURGICAL IMPLANTS | |
EP2170950A4 (en) | ANTI-IL-20 ANTIBODIES AND ITS USE IN THE TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH IL-20 | |
PL1912650T3 (pl) | Zastosowanie flibanseryny w leczeniu otyłości | |
PT2291394T (pt) | Proteínas de fusão e seus usos no diagnóstico e tratamento de leishmaniose | |
EP1862470A4 (en) | ELEMENT RETAINED IN BLOOD SHOWING SELECTIVE DEGRADABILITY IN TUMOR TISSUE | |
GB0519046D0 (en) | Improvements in and relating to cleaning | |
GB0513193D0 (en) | Improvements in skin and hair care | |
EP2323680A4 (en) | PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES | |
GB0515758D0 (en) | Improvements in and relating to optical coherence tomography | |
EP2089420A4 (en) | PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES | |
GB2431356B (en) | Improvements in and relating to disposable dispensers for personal use | |
GB0502990D0 (en) | Improvements in and relating to identifier investigation | |
IL212214A0 (en) | Use of lipid conjugates in the treatment of disease | |
EP1977003A4 (en) | DISEASE-RELATED METHODS AND MEDIUM | |
GB0523166D0 (en) | Improvements in and relating to medical products | |
EP1942911A4 (en) | THERAPEUTIC MOLECULES AND USES THEREOF | |
IL185575A0 (en) | Benzoxazocines and their therapeutic use | |
GB0516392D0 (en) | Improvements in and relating to wool treatment | |
ZA200802541B (en) | Human antibodies against IL13 and therapeutic uses | |
GB0718156D0 (en) | Improvements in and relating to investigations | |
GB0606484D0 (en) | Improvements in and relating to instruments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210129 |